Teradyne (TER) Q2 2025 10-Q Quarterly Report
Filed: Aug 1, 2025Period ending Jun 29, 2025
Health Care
Instruments For Meas & Testing of Electricity & Elec SignalsSEC EDGAR Teradyne (TER) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 1, 2025 for the fiscal period ending Jun 29, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Teradyne Q2 2025 10-Q Analysis
Risk Factors
- • No new risk factors added this quarter; critical accounting policies unchanged from 2024 10-K
- • Most materially updated risk: Semiconductor Test revenue decline 12.1% QoQ due to memory market weakness
- • Regulatory/legal risk: Compliance with US Tax Cuts and Jobs Act benefits reduces effective tax rate to 12.7% vs 15.1% prior year
- • Operational risk: Robotics segment sales drop 17.0% QoQ amid collaborative robotic arms market weakness impacting near-term results
- • Financial risk: Cash balances down $235.2M to $488.6M on share repurchases ($274.9M), acquisitions ($144.4M), and capex ($114.4M)
Teradyne Q2 2025 Quarterly FinancialsXBRL
Revenue
$652M
▼ -10.7% YoY▼ -4.9% QoQ
Net Income
$78M
▼ -57.9% YoY▼ -20.8% QoQ
Net Margin
12.0%
▼ -1350bp YoY▼ -240bp QoQ
Source: XBRL data from Teradyne Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Teradyne Quarterly Reports
Get deeper insights on Teradyne
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.